ArticleJournal of global oncology2018
Global Access to Essential Medicines for Childhood Cancer: A Cross-Sectional Survey.
Article in Journal of global oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Worldwide Trends in Survival From Common Childhood Brain Tumors: A Systematic Review.Journal of global oncology · 2019Pooled it
- Pediatric H3 G34-mutant diffuse hemispheric glioma: clinical, imaging and molecular prognostic factors, MGMT expression, and temozolomide response.Acta neuropathologica · 2026Article
- Epidemiology of childhood cancer in Asia.EClinicalMedicine · 2025Review
- Medicine availability and affordability for paediatric cancers, China.Bulletin of the World Health Organization · 2025Article
- 'Challenges in pediatric medicine access in Albania: insights from community Pharmacists'.Journal of pharmaceutical policy and practice · 2025Article
- Article
- Closing the gap: National Argentinian discussion forum on paediatric brain tumours.Frontiers in oncology · 2023Article
- Twelve-month observational study of children with cancer in 41 countries during the COVID-19 pandemic.BMJ global health · 2022Observational
- Defining Essential Childhood Cancer Medicines to Inform Prioritization and Access: Results From an International, Cross-Sectional Survey.JCO global oncology · 2022Article
- Impact of Allocation on Survival During Intermittent Chemotherapy Shortages: A Modeling Analysis.Journal of the National Comprehensive Cancer Network : JNCCN · 2022Article
- Accessibility of essential anticancer medicines for children in the Sichuan Province of China.Frontiers in public health · 2022Article
- Curing the Curable: Managing Low-Risk Acute Lymphoblastic Leukemia in Resource Limited Countries.Journal of clinical medicine · 2021Review
- Evaluation of the Pediatric Neuro-Oncology Resources Available in Chile.JCO global oncology · 2021Article
- Shortages and price variability of essential cytotoxic medicines for treating children with cancers.BMJ global health · 2020Article
- Article
- Estimating the impact of treatment and imaging modalities on 5-year net survival of 11 cancers in 200 countries: a simulation-based analysis.The Lancet. Oncology · 2020Article
- Global comparison of cancer outcomes: standardization and correlation with healthcare expenditures.BMC public health · 2019Article
- Outcomes of pediatric medulloblastoma in low- and middle-income countries: A retrospective analysis of 335 cases from 8 countries.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGlobal data mapping access to essential chemotherapeutics for pediatric cancer are scarce. We report a survey of international pediatric cancer care providers' access to these medicines.
methodsA Web-based survey was sent to pediatric oncologists registered on the Cure4Kids Web portal. We queried chemotherapeutics in the WHO Essential Medicines List for Children, from which the average proportional availability was summarized as each country's access score. In addition, we examined availability of drug packages defined by the WHO-sanctioned Expert Committee for eight pediatric cancers. We undertook a sensitivity analysis investigating how regimen access would change if the cytotoxics specified in recent agreements between the Clinton Health Access Initiative, American Cancer Society, and pharmaceutical companies were universally available.
resultsThere were significant ( P < .001) differences in the median access scores between World Bank income groups, and 42.9% of respondents from low-income and lower middle-income countries reported suboptimal access scores. Our disease-based analysis revealed that 42.1% of patients in low-income and lower middle-income countries lacked full access to chemotherapy packages. Guaranteed availability of the cytotoxics specified in the Clinton Health Access Initiative/American Cancer Society agreements was projected to increase this regimen-based access by 1.6%, although including four additional chemotherapeutics would further increase coverage by 13.9%.
conclusionThis study is the first, to our knowledge, to assess worldwide variation in practical access to pediatric chemotherapy. Although mapping the proportion of available chemotherapeutics is informative, we also developed a meaningful estimate of access using disease-specific drug packages. These data provide an important baseline for continued monitoring and can aid in planning adaptive treatment guidelines that consider the trade-offs between access and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.